      Document 0004
 DOCN  DRG0004
 UNIQUE IDENTIFIER        DRG-0243
 NAME OF SUBSTANCE        ALVAC-HIV MN120TTMGNP (vCP300) [NIAID VEU
                          026]
 PROTOCOL ID NUMBERS      NIAID VEU 026
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   MODE OF ACTION: Can induce cellular and
                          humoral responses in animals. In previous
                          experiments with mice, vCP300 induced a
                          cytotoxic response against target cells with
                          the V3 peptide and gag/pol epitopes and a
                          proliferative response to gp160. In vitro, it
                          has been shown to stimulate CD8+
                          env/gag/nef/pol specific CTL precursors
                          present in PBMCs derived from
                          HIV-seropositive patients. [NIAID VEU 026]
 DISEASES STUDIED/TREATED Prevention of HIV infection [NIAID VEU 026]
 CLASSIFICATION CODE      Vaccine [NIAID VEU 026]
 ADVERSE EFFECTS          Adverse effects may include pain, soreness,
                          redness, and swelling at the site of
                          injection. Fever, chills, rash, aches and
                          pain, nausea, headache, fatigue, and allergic
                          reactions such as hives or difficulty
                          breathing may also occur. [NIAID VEU 026]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Immunogen constructed from
                          a live recombinant canarypox vector;
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: it is a complex antigen
                          consisting of MN gp120, plus the
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: transmembrane portion of
                          HIV-1 LAI gp41 as well as HIV-1 gag,
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: protease, and multiple CTL
                          epitopes in nef and and pol gene products
                          [NIAID VEU 026]
 CHEMICAL/PHYSICAL DATA   PHYSICAL DATA: pH 7.62. [NIAID VEU 026]
 CHEMICAL/PHYSICAL DATA   PHYSICAL DESCRIPTION: White to pink in
                          lyophilized form; slightly opalescent, pink
                          to purplish-blue after reconstruction [NIAID
                          VEU 026]
 SUBSTANCE DELIVERY DATA  DOSAGE FORM: 1.0 ml vials containing 1.3
                          million TCID50. [NIAID VEU 026]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Intramuscular. [ NIAID VEU
                          026]
 SUBSTANCE DELIVERY DATA  STORAGE INSTRUCTIONS: Store lyophilized
                          vaccine at -20 C. [NIAID VEU 026]
 MANUFACTURERS            Pasteur Merieux Serums et Vaccins
 ENTRY MONTH              9603
 LAST REVISION DATE       960313
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
